Compare TAP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAP | NUVL |
|---|---|---|
| Founded | 1873 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.1B |
| IPO Year | N/A | 2021 |
| Metric | TAP | NUVL |
|---|---|---|
| Price | $46.56 | $99.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $50.31 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 3.1M | 443.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.85 | N/A |
| Revenue Next Year | $0.14 | $1,064.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.94 | $55.54 |
| 52 Week High | $64.66 | $113.02 |
| Indicator | TAP | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 42.84 |
| Support Level | $45.23 | $98.65 |
| Resistance Level | $47.69 | $107.13 |
| Average True Range (ATR) | 1.45 | 4.05 |
| MACD | -0.45 | -0.31 |
| Stochastic Oscillator | 6.98 | 19.28 |
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.